NUP85 and metabolic dysfunction-associated steatohepatitis: approximately 10–20% of NASH patients may progress to liver fibrosis, cirrhosis, and even LC (Kessoku et al. 2021), indicating that NUP85 is likely associated with the early tumorigenesis of LC.